Awakn Life Sciences (OTCMKTS:AWKNF – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Analyst Ratings
This is a breakdown of recent recommendations for Awakn Life Sciences and Sarepta Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Awakn Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Sarepta Therapeutics | 5 | 6 | 9 | 0 | 2.20 |
Sarepta Therapeutics has a consensus price target of $25.06, suggesting a potential upside of 20.97%. Given Sarepta Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Awakn Life Sciences.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Awakn Life Sciences | N/A | N/A | N/A | N/A | N/A |
| Sarepta Therapeutics | $1.97 billion | 1.11 | -$713.41 million | ($2.90) | -7.14 |
Awakn Life Sciences has higher earnings, but lower revenue than Sarepta Therapeutics.
Profitability
This table compares Awakn Life Sciences and Sarepta Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Awakn Life Sciences | N/A | N/A | N/A |
| Sarepta Therapeutics | -13.48% | -1.60% | -0.66% |
Institutional & Insider Ownership
86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Sarepta Therapeutics beats Awakn Life Sciences on 6 of the 9 factors compared between the two stocks.
About Awakn Life Sciences
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Awakn Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Awakn Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
